Announcing Learn: OpenEvidence's Personalized Medical Education Platform

MIAMI--(BUSINESS WIRE)-- OpenEvidence, the most popular AI for doctors in the United States, today launched Learn: a free, personalized medical education platform built to support trainees and clinicians across their entire careers. As AI transforms work, it has never been more important to ensure the technology strengthens learning as well. OpenEvidence has been widely adopted by clinicians as an essential tool at the point of care, and is now applying that same technology to reimagine not just how doctors practice medicine, but how they learn it. Developed in collaboration with leading medical institutions, certifiers, and educators, Learn brings together a suite of tools built on OpenEvidence to give every trainee and clinician a tailored, evidence-based learning experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104765459/en/

OpenEvidence Learn, a personalized medical education platform for every stage of a clinician's career.

Available today on the OpenEvidence personalized medical education platform:

• Test Prep: 50,000+ board-style questions for deliberate evidence-based practice for medical school, residency, fellowship, and board exams, including USMLE, COMLEX, and specialty and subspecialty boards.
• Preceptor: Socratic, case-based tutoring with AI. Work up a simulated patient at your level of training, across specialties and clinical settings.
• Flashcards: Generate flashcards from your OpenEvidence questions, missed Test Prep questions, or any topic of interest. Cards can be reviewed at spaced intervals to strengthen retention.
• CME: Earn credit for the clinical questions you already ask. All certificates are kept in one place.

Learn draws on the same continuously updated foundation of peer-reviewed evidence and clinical guidelines that power OpenEvidence answers, so every question, case, and flashcard reflects how medicine is practiced today.

“Medicine has always asked us to be students for life. What has changed is the pace of new evidence and the power of the tools we use to keep up with it. The best clinicians stay curious and keep asking questions. Our goal with Learn is to encourage continual learning and sound clinical judgment,” said Vishal Patel, MD, VP of Clinical Partnerships and AI Education at OpenEvidence.

The platform will grow over time with additional tools for active learning and clinical reasoning, built alongside leading medical schools, residency programs, and medical educators. OpenEvidence is partnering with leading medical schools, including Johns Hopkins University School of Medicine and the Perelman School of Medicine at the University of Pennsylvania, to invite their trainees and attending physicians to explore the platform and share feedback. Their input will guide Learn’s development, helping tailor its tools to the curricula and training needs of participating programs.

OpenEvidence Learn is available today, free to all OpenEvidence users. Go to www.openevidence.com/learn.

About OpenEvidence

OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world’s collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104765459/en/

OpenEvidence: [email protected]

Source: OpenEvidence

You May Also Be Interested In

• MSCI November Index Review Announcement Scheduled for November 11, 2026
• KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-MED3 (SEMT 2026-MED3)
• Evommune Announces $30 Million Private Placement